Trial Profile
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Subjects With Moderate to Severe Systemic Lupus Erythematosus (SLE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Cenerimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms CARE
- Sponsors Idorsia Pharmaceuticals
- 15 Nov 2023 Results of post-hoc analysis in sub-group of patients with high IFN-1 gene expression signature or anti-dsDNA levels >30 IU/mL presented at the ACR Convergence 2023
- 15 Nov 2023 Results assessing the leukocytes, autoantibodies, and inflammation biomarkers of once-daily cenerimod (0.5, 1, 2, or 4 mg) versus placebo in patients with SLE from NCT02472795 and NCT03742037 trials, presented at the ACR Convergence 2023.
- 07 Aug 2023 Number of treatment arms has been changed to 7 from 11.